Laura Heiser

laura heiser

Phone: 503 346-4617
Fax: 503 494-6886

Current Appointment
Associate Professor

Collaborative Life Sciences Building (CLSB)
Mail Code: CL3G
2730 SW Moody Avenue, Portland, OR 97201

B.A., University of California, Berkeley, 1998
Ph.D., University of Pittsburgh, 2004

Research Area
OHSU Center for Spatial Systems Biology

Research Interests

Dr. Heiser's research is focused on identifying pathways and aberrations associated with therapeutic response and resistance in cancer. In her studies, she uses an integrative systems biology approach to understand cancer as a complex system. Dr. Heiser is also an active member of the DREAM Consortium, which is a community-based effort to rigorously assess and advance algorithms in computational biology.

Selected Publications

1.     Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2015 Aug 6. pii: molcanres.0189.2015.

2.     Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res. 2015 May 26

3.     Bansal M, Yang J, Karan C, Menden, MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez M, Shen Y, NCI-DREAM community, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A. The challenge of predicting synergistic and antagonistic compound-pair activity from individual compound predictions. Nat Biotechnol. 2014 Dec;32(12):1213-22.

4.     Costello JC*, Heiser LM*, Georgii E*, Gonen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi J-P, NCI DREAM Community, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G. A community effort to assess drug sensitivity prediction algorithms identifies approaches for improved performance. Nat. Biotech. 2014 Dec;32(12):1202-12.

5.     Daemen A*, Griffith OL*, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Modeling precision treatment of breast cancer. Genome Biol. 2013 Oct21; 14(10):R110.

6.     Griffith OL, Pepin F, Enache OM, Heiser LM, Collisson EA, Spellman PT, Gray JW. A robust prognostic signature for hormone-positive node-negative breast cancer. Genome Med. 2013 Oct 11;5(10):92.

7.     Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 2013 Nov;9(11):708-14.

8.     Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S. Bayesian Inference of Signaling Netowrk Topology in a Cancer Cell Line. Bioinformatics. 2012 Aug 24.

9.     Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A Central Role for RAF->MEK->ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2012 Jul 26.

10.  Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev L, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.  Subtype and pathway specific responses to anti-cancer compounds in breast cancer. PNAS, 2012 Feb 21;109(8):2724-9.

11.  The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.  Nature 2011 Jun 29; 474(7353):609-15.

12.  Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, Marton LJ, Gray JW. A systems analysis of chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.  BMC Med. 2009 Dec 14; 7:77.

13.  Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, Hu Z, Ziyad S, Weber B, Laquerre S, Jackson JR, Wooster RF, Kuo WL, Gray JW, Spellman PT.  Integrated analysis of breast cancer cell lines reveals unique signaling pathways.  Genome Biol. 2009 Mar 25;10(3):R31.

14.  Mirozeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Parvin B, Knight Z, Feiler HS, Gascard P, Spellman PT, Shokat KM, Wyrobek A, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn M. Basal-subtype and MEK-PI3K feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.  Cancer Res. 2009 Jan 15;69(2):565-72.